Skip to main content

Advertisement

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

  • 166 Accesses

The original article was published in BMC Health Services Research 2019 19:827

Correction to: BMC Health Serv Res

https://doi.org/10.1186/s12913-019-4680-2

In the original publication of this article [1], there is a mistake in the Fig. 2a, b, and c. The mistake is in the very last column where it shows TOTAL. The updated Fig. 2 is shown below. Additionally, a footnote “Total is based on the average discounted price amongst all provinces.” should be added to Table 2 and Additional files 1, 2, and 3.

Fig. 2
figure1

a. Overall units purchased of insulin glargine by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Basaglar® were purchased instead of the originator drug Lantus®. b Overall units purchased of filgrastim by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Grastofil® were purchased instead of the originator drug Neupogen®. c Overall units purchased of infliximab by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Inflectra® were purchased instead of the originator drug Remicade®

Table 2 Realized and Unrealized Savings for the biosimilars Basaglar®, Grastofil®, and Inflectra® Relative to Captured Market Share by Province

Reference

  1. 1.

    Mansell K, et al. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. BMC Health Serv Res. 2019;19:827.

Download references

Author information

Correspondence to Kerry Mansell.

Additional information

The original article can be found online at https://doi.org/10.1186/s12913-019-4680-2

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mansell, K., Bhimji, H., Eurich, D. et al. Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. BMC Health Serv Res 19, 972 (2019) doi:10.1186/s12913-019-4829-z

Download citation